{"Clinical Trial ID": "NCT00201864", "Intervention": ["INTERVENTION 1:", "- Exemestane and Fulvestrant", "Combination of daily exemestane 25 mg with a monthly injection of Fulvestant 250 mg", "Exemestane: 25 mg orally daily", "Fluvestant: 250 mg of IM from day 8 and every 28 days."], "Eligibility": ["Incorporation criteria:", "Proven breast cancer", "Metastatic or locally advanced breast cancer", "A hormone response disease defined as positive for estrogen (ER) and/ or progesterone (PR) receptors (> 10% immunohistochemistry staining)", "Postmenopausal situation", "No more than one prior chemotherapy for stage IV metastatic breast cancer authorised", "ECOG (Eastern Cooperative Oncology Group) Statement of Operations 0-2", "Adequate function of the organ", "- Exclusion criteria:", "No previous exemestane or fulvestrant", "An uncontrolled intercurrent disease, including, but not limited to:", "Current or active infection", "- Symptomatic congestive heart failure", "\u266a Unstable angina pectoris \u266a", "Cardiac arrhythmia", "Myocardial infarction in the last 3 months", "Psychiatric diseases/social situations that would limit compliance with the study", "\u2022 Lymphangitis pulmonary disease; carcinoma meningitis, bone marrow metastases only; and a tumor marker growing without any other metastatic disease site.", "Presence of haemorrhagic diathesis or coagulopathy, patients requiring coumadine"], "Results": ["Performance measures:", "Time of progression (TTP) in women with advanced hormonal receptive breast cancer treated with exemestane and fulvestrant.", "The progression is defined using the criteria for assessing response in solid tumours (RECIST v1.0), such as a 20% increase in the sum of the longest diameter of the target lesions, or a measurable increase in non-target injury, or the occurrence of new lesions.", "Calendar: Every 2 cycles up to 2 years", "Results 1:", "Title of the arm/group: Exemestane and Fulvestant", "Description of the arm/group: Combination of daily exemestane 25 mg with a monthly injection of Fulvestant 250 mg", "Exemestane: 25 mg orally daily", "Fluvestant: 250 mg of IM from day 8 and every 28 days.", "Total number of participants analysed: 40", "Median (95% confidence interval)", "Unit of measure: month 6.9 (3.9 to 13.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/40 (15.0%)", "1/40 (2.50%)", "- Vomiting 1/40 (2.50%)", "1/40 chest pain (2.50%)", "Hypercalcaemia 1/40 (2.50%)", "Thromboembolism 2/40 (5.0%)"]}